Physician profile
Ginger Weaver
NPI 1134708266
$1,790.32
in general payments reported to CMS, 2019-2025
16 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $453 · 2022: $782 · 2024: $259 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $347.40 | 2021-2022 | |
| Merz North America, INC. | $278.36 | 2025 | |
| Revance Therapeutics, INC. | $242.10 | 2024-2025 | Daxxify |
| Abbvie INC. | $183.10 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $172.99 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.66 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $72.68 | 2021-2022 | |
| Janssen Biotech, INC. | $71.75 | 2022 | |
| Amgen INC. | $65.67 | 2021-2022 | |
| Celgene Corporation | $27.93 | 2022 | |
| Evoke Pharma, INC. | $27.22 | 2022 | |
| Alfasigma USA, INC. | $25.87 | 2022 | |
| Braintree Laboratories, INC. | $20.27 | 2022 | |
| Vivus LLC | $15.78 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.